Citadel Advisors’s Tango Therapeutics TNGX Stock Holding History

Citadel Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$464K	Buy	+22,200	New	+$309K	﹤0.01%	9485
2025 Q3	–	Sell	-16,200	Closed	-$82.9K	–	14123
2025 Q2	$82.9K	Buy	+16,200	New	+$40.1K	﹤0.01%	11471
2025 Q1	–	Sell	-4,400	Closed	-$13.6K	–	15574
2024 Q4	$13.6K	Buy	4,400 +2,900	+193%	+$13.5K	﹤0.01%	13436
2024 Q3	$11.6K	Buy	1,500 +500	+50%	+$4.77K	﹤0.01%	13153
2024 Q2	$8.58K	Sell	1,000 -600	-38%	-$4.64K	﹤0.01%	13180
2024 Q1	$12.7K	Buy	+1,600	New	+$17.1K	﹤0.01%	13350

Other funds holding TNGX

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Citadel Advisors's TNGX Position: Q1 2026 in Review

Citadel Advisors increased its Tango Therapeutics (TNGX) stake by 18% in Q1 2026, buying an estimated $383K and bringing the position to 179,423 shares worth $3.75M. The position accounts for ﹤0.01% of the portfolio, ranked #4835.

Citadel Advisors first reported a position in TNGX in Q3 2020 and has held it in 21 quarters since. The position peaked at $20.7M in Q3 2024. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

Citadel Advisors held 179,423 shares of Tango Therapeutics worth $3.75M as of Q1 2026.
Citadel Advisors bought 27,543 Tango Therapeutics shares in Q1 2026, an estimated $383K.
Tango Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4835 holding.
Citadel Advisors first reported a position in Tango Therapeutics in Q3 2020 and has held it in 21 quarters since.
Citadel Advisors's Tango Therapeutics position peaked at $20.7M in Q3 2024.
194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.